A new retrospective study from Greek researchers, published in the Archives of Dermatological Research, tackles precisely that question by measuring relapse kinetics, the speed and pattern with which actinic keratoses return after treatment. The team, led by Despina Exadaktylou and Ioannis D. Bassukas with colleagues in Athens and Ioannina, compared three real-world regimens used on the head: cryosurgery alone, cryosurgery followed by daylight photodynamic therapy, and cryosurgery followed by four weeks of topical imiquimod, an immune-response modifier applied as a cream. Their central finding is striking. The combination of mild freezing followed by a month of imiquimod produced a therapeutic effect lasting on average about fourteen months, significantly longer than either cryosurgery alone or cryosurgery paired with daylight photodynamic therapy, both of which delivered roughly eight to eight and a half months of benefit before relapse set in.

The study owes its unusual design to an unexpected legacy of the COVID-19 pandemic. During lockdowns, routine dermatology follow-ups across Greece and much of Europe were postponed, sometimes for many months or even years. For patients treated for field cancerization before the pandemic, that disruption meant the interval between treatment and the first post-treatment skin examination stretched far beyond the usual clinical schedule. Rather than discarding these irregular records, the researchers recognized them as a natural experiment: a dataset in which follow-up times varied enormously, from as little as twenty-eight days to as long as 1,379 days after the cryosurgery session that began each treatment cycle. That variation, normally a nuisance in clinical research, allowed them to trace how disease burden evolved across a much wider window of time than a conventional fixed-schedule study could capture.

The analysis included 116 treatment cycles involving head-located field cancerization regions in 30 patients, 27 of them men, with a median age of 81 years. The treated areas comprised 83 scalp regions, 26 forehead regions, and 7 cheek regions. Forty cycles were treated with cryosurgery monotherapy, 27 with the combination of cryosurgery and daylight photodynamic therapy, and 49 with cryosurgery plus imiquimod. To quantify disease burden, the team used a modified version of the Actinic Keratosis Area and Severity Index, known as AKASI, restricted to the treated head subregions. By scoring the same anatomical area before treatment and again at the first follow-up visit, they could calculate a change-from-baseline that reflected how much the treatment had actually improved the field, and how much of that improvement had eroded by the time the patient returned.

The statistical machinery behind the study combined nonparametric comparisons with survival analysis, a technique more familiar from oncology trials tracking time to tumor recurrence. Wilcoxon and Kruskal-Wallis tests assessed differences in continuous measures such as AKASI scores, while Kaplan-Meier curves and Cox proportional hazards methods modeled the time until relapse, defined through the first post-treatment evaluation for each therapy cycle. Significance was set at a two-tailed probability level below 0.05. This survival-style framing is what makes the study’s headline numbers meaningful: instead of simply asking whether patients improved, the researchers asked how long the improvement endured, treating the disappearance of the therapeutic effect as an event that could be timed and compared across the three treatment arms.

The results tell a nuanced story. Immediately after treatment, only the two combination modalities produced a statistically significant improvement in the field: the reductions in AKASI scores were significant for cryosurgery plus daylight photodynamic therapy and for cryosurgery plus imiquimod, while cryosurgery alone did not reach significance for initial field improvement. More importantly, that early advantage faded as follow-up time lengthened, a pattern the authors describe as the initial improvement vanishing with increasing time to first evaluation. In other words, the visible benefit of field treatment is real but transient, and the longer one waits before examining the skin, the less distinguishable the treated field becomes from its pretreatment state. This modality-independent erosion of benefit underscores why time-to-relapse, rather than short-term clearance rates, should be the metric that guides treatment planning.

When the duration of the therapeutic effect was compared directly, the differences between regimens became clear. Cryosurgery monotherapy yielded a mean effect duration of 8.34 months, with a 95 percent confidence interval spanning 5.21 to 11.48 months. Cryosurgery combined with daylight photodynamic therapy performed almost identically, at 8.53 months with a confidence interval of 4.16 to 12.90 months. Cryosurgery followed by four weeks of imiquimod, by contrast, extended the mean effect duration to 14.15 months, with a confidence interval of 9.94 to 18.37 months. Both combination regimens were significantly superior to cryosurgery alone, but the imiquimod combination was also significantly superior to the photodynamic therapy combination, with the Kaplan-Meier analysis yielding p values of 0.007 and 0.032 for the respective comparisons. For elderly patients, many of whom face repeated treatment cycles over decades, an extra five to six months of clearance per cycle is a clinically meaningful gain.

The biological logic behind this result is consistent with what is known about how these therapies work. Cryosurgery physically destroys visible lesions but does little to address the microscopic field of mutated cells surrounding them. Daylight photodynamic therapy uses a topical prodrug, methyl aminolevulinate, which is converted into a photosensitizer inside abnormal cells; exposure to daylight then triggers reactive oxygen species that kill those cells, with the advantage of being nearly painless compared with conventional artificial-light photodynamic therapy. Imiquimod takes a different route entirely: it activates toll-like receptor 7 on immune cells, unleashing a localized innate and adaptive immune response that targets genetically damaged keratinocytes over the weeks the cream is applied. The longer relapse time observed with the immunocryosurgery approach suggests that recruiting the patient’s own immune system to patrol the treated field provides a more durable suppression of residual disease than a single photodynamic insult, even when both are anchored by the same cryosurgery session.

The authors are candid about the limitations of their work. The study is retrospective, relies on chart review, involves a small number of patients and treatment cycles, and draws all of its data from a single clinical setting. The wildly variable follow-up times, while analytically exploitable, also mean that the relapse estimates depend on the assumption that a single post-treatment evaluation can represent the state of the field at that moment. The patient population, overwhelmingly elderly men with scalp disease, may not generalize to other groups. Still, the study was conducted under institutional ethical approval and in accordance with the Helsinki Declaration, and the authors report no funding and no competing interests. As a first quantitative map of relapse kinetics after field treatment with adjuvant cryosurgery, it offers something the field has lacked: a timeline. If confirmed in larger, prospective studies, the message for clinicians managing cutaneous field cancerization could be simple and consequential, namely that when the goal is to keep sun-damaged skin clear for as long as possible, a month of immune activation after freezing may be worth more than a day in the sun.

Subject of Research: Relapse kinetics of actinic keratoses after field treatments combining cryosurgery with daylight photodynamic therapy or topical imiquimod

Article Title: Relapse kinetics of actinic keratoses after field treatments with adjuvant cryosurgery: a retrospective study of cases with variable follow-up times

Article References: Exadaktylou, D., Chroni, P., Stefaniotou, S., Spyridonos, P., Gaitanis, G., & Bassukas, I. D. (2026). Relapse kinetics of actinic keratoses after field treatments with adjuvant cryosurgery: a retrospective study of cases with variable follow-up times. Archives of Dermatological Research, 318(1), Article 443. https://doi.org/10.1007/s00403-026-04931-x

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04931-x

Keywords: actinic keratosis, cutaneous field cancerization, cryosurgery, imiquimod, daylight photodynamic therapy, relapse kinetics, AKASI score, Kaplan-Meier analysis, skin cancer prevention, retrospective study, COVID-19 pandemic, dermatology

The research team, led by Fakhriyeh Kelavari of the Department of Pathology at Razi Hospital, Guilan University of Medical Sciences in Rasht, examined 602 skin biopsy samples collected over three years. The samples included 352 benign lesions and 250 malignant or premalignant ones, spanning a wide diagnostic spectrum: melanocytic nevi, sebaceous nevi, vascular lesions, seborrheic keratoses, actinic keratoses, basal cell carcinoma, basosquamous cell carcinoma, and squamous cell carcinoma. By analyzing routine histopathological sections, the researchers could identify mites lodged within follicles and compare infestation rates across diagnostic categories, patient ages, sexes, and anatomical sites.

The headline result was striking. Demodex infestation was detected in 23.6 percent of malignant lesions but only 10.5 percent of benign ones, a difference the authors report as highly statistically significant, with a P value below 0.001. Significant differences also emerged between the two groups in age, sex, and lesion location, reflecting the well-known demographic patterns of skin cancer, which tends to appear in older patients and on sun-exposed sites. The study was designed specifically to compare infestation frequencies between benign and malignant lesions in order to explore whether mites might act as a triggering factor in skin tumor development.

Within the benign group, the distribution of mites was far from uniform. Sebaceous nevi, benign growths of oil gland tissue, showed the highest infestation rate at 38.5 percent, followed by vascular lesions at 15.4 percent, melanocytic nevi at 13.8 percent, and seborrheic keratoses at 11.6 percent. Sebaceous nevi are of particular interest because they contain abundant, enlarged sebaceous glands, and Demodex mites feed on sebum, the oily secretion those glands produce. A dense lipid-rich environment could plausibly support larger mite populations, which may explain why these lesions harbored mites so frequently compared with other benign growths.

The malignant group told an even more compelling story. Actinic keratosis, a sun-induced premalignant scaly patch that can progress to squamous cell carcinoma, was the most heavily infested diagnosis of all, with mites present in 55.6 percent of cases. The authors note that actinic keratosis was significantly more infested than the other malignant lesions, with a P value below 0.001. Basosquamous cell carcinoma, an aggressive variant that shares features of both basal and squamous cell cancers, came next at 27.3 percent, followed by the most common skin cancer, basal cell carcinoma, at 25.2 percent, and squamous cell carcinoma at 14.6 percent. The gradient across these diagnoses hints that local tissue changes in chronically sun-damaged skin may create conditions that favor mite colonization.

What could connect a follicle-dwelling mite to tumor biology? Several mechanisms have been proposed in the broader literature. Demodex mites provoke inflammatory reactions as they feed, damage follicular epithelium with their claws and mouthparts, and can carry surface bacteria, including Bacillus species, whose proteins are thought to trigger the immune cascades seen in rosacea. Chronic inflammation is a well-established driver of carcinogenesis in many tissues, and the skin is no exception. The mites also interact with the cutaneous immune system in complex ways; recent immunology work has shown that type 2 innate lymphoid cells, the same immune population implicated in anti-melanoma responses, help control Demodex commensalism in hair follicles, suggesting a potential immunological crossroad between mite burden and tumor surveillance.

The new findings align with a growing but still scattered body of evidence. Earlier studies have detected Demodex in actinic keratosis and nonmelanoma skin cancer biopsies, reported associations between mite infestation and various cancers in different patient groups, and described Demodex-induced cutaneous pseudolymphoma, a benign inflammatory mass that mimics lymphoid tumor. Researchers have also documented mites within melanocytic nevi and eyelid tumors, and a 2022 report in the Journal of Dermatology for Physician Assistants specifically examined Demodex in patients with non-melanoma skin cancer. Meanwhile, studies of the skin microbiome in cutaneous squamous cell carcinoma have shown that microbial communities shift as cancer progresses, reinforcing the idea that the follicular ecosystem is altered in malignant skin.

Yet the authors are careful about the direction of causality, and they explicitly acknowledge the central limitation of their study: it is cross-sectional, capturing a single moment in time. As they state, it is not clear whether Demodex infestation occurred first or the skin tumors did. Malignant and chronically sun-damaged skin undergoes structural changes, including altered follicular architecture, disrupted barrier function, and modified sebum production, any of which could make tissue more hospitable to mites rather than the mites initiating the tumor. Reverse causation remains a live possibility, and only longitudinal studies that track infestation and tumor development over time in the same patients could disentangle which comes first.

Confounding factors also complicate the interpretation. Age is strongly associated with both Demodex density and skin cancer risk, and although the study found significant differences in age between the benign and malignant groups, the analysis did not fully isolate mite infestation from age, sex, and anatomical site effects. Sun-exposed skin, where actinic keratoses arise, is also the skin most altered by years of ultraviolet damage, and damaged follicles may simply be easier for mites to colonize. The authors report that no datasets were generated or analyzed beyond the study itself, and the work was approved by the ethics committee of Guilan University of Medical Sciences as part of a residency thesis, underscoring that this is an early observational signal rather than a definitive mechanistic demonstration.

Even with those caveats, the study is one of the largest direct comparisons of Demodex burden in benign versus malignant skin lesions, and its scale gives the association weight that smaller case reports could not. If future prospective research confirms that mite infestation precedes malignant transformation in some lesions, Demodex density could eventually become a biomarker worth monitoring in high-risk patients, or even a therapeutic target, much as mite-directed treatments have transformed the management of rosacea. For now, the image that emerges is of a familiar microscopic companion whose presence in tumor tissue is far from random, and whose role in the life story of a skin tumor, passenger or provocateur, remains one of dermatology’s most intriguing open questions.

Subject of Research: Association between Demodex mite infestation and benign versus malignant skin tumors

Article Title: Demodex infestation in benign and malignant skin tumors

Article References: Kelavari, F., Rafiei, R., Alizadeh, N., Gharaei Nejad, K., Eftekhari, H., Skandarzadeh, P., & Rafiei, E. (2026). Demodex infestation in benign and malignant skin tumors. Archives of Dermatological Research, 318(1), Article 483. https://doi.org/10.1007/s00403-026-04910-2

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04910-2

Keywords: Demodex, skin cancer, basal cell carcinoma, actinic keratosis, squamous cell carcinoma, melanocytic nevi, sebaceous nevi, histopathology, parasitology, dermatology, skin microbiome, retrospective study

The study, conducted by Joseph McGrath, Evelyn Fagan, Kaeli Samson, Yue Zhan, and Adam Sutton, was approved by the University of Nebraska Medical Center’s institutional review board and carried out in accordance with the Declaration of Helsinki, with written informed consent obtained from every participant. The research team set out to systematically compare what patients say about their own skin lesion histories against clinical verification, a comparison that matters enormously because the entire architecture of skin cancer surveillance in many health systems rests on self-reported data gathered in intake questionnaires and verbal histories.

Actinic keratoses are rough, scaly patches that develop on chronically sun-exposed skin, most often in fair-skinned, older adults. They are technically keratinocyte dysplasias rather than frank malignancies, but they occupy a critical position on the continuum of cutaneous carcinogenesis. A subset of them can progress to squamous cell carcinoma, and their presence signals what dermatologists call field cancerization, a state in which broad swathes of skin have sustained enough ultraviolet damage that multiple lesions can arise simultaneously and independently across the affected area. Keratinocyte carcinomas, meanwhile, encompass basal cell carcinoma and squamous cell carcinoma, the two most frequent cancers in fair-skinned populations worldwide and cancers whose incidence continues to climb as populations age and cumulative ultraviolet exposure accumulates.

The problem with relying on patient recall for these conditions is baked into their biology and their clinical course. Actinic keratoses are frequently treated with destructive methods such as cryotherapy, in which liquid nitrogen obliterates the lesion without any tissue being sent to a pathology laboratory. A patient who has had a dozen such treatments over twenty years may genuinely not know whether any given rough patch was confirmed as an actinic keratosis, whether it was something benign like a seborrheic keratosis, or whether it was an early squamous cell carcinoma that was frozen off preemptively. The diagnostic label often exists only in billing codes or in the memory of a clinician the patient saw years ago, if it exists at all.

Keratinocyte carcinomas present a related but distinct recall challenge. Basal cell carcinomas are rarely life-threatening but frequently recur, and patients with one history of nonmelanoma skin cancer face substantially elevated odds of developing subsequent lesions, a relationship established in meta-analytic work going back to Marcil and Stern’s widely cited 2000 review in the Archives of Dermatology. Squamous cell carcinomas carry greater metastatic potential, making accurate history-taking even more consequential. If a patient underreports a prior squamous cell carcinoma, a clinician may underestimate risk and calibrate follow-up too loosely. If a patient overreports, the result can be unnecessary anxiety, redundant biopsies, and wasted health system resources. Either direction of error degrades the precision of epidemiological studies that depend on self-reported cancer histories as their exposure variable.

This is not the first time the validity of patient self-report in dermatology has been scrutinized. A landmark 2004 study by Ming and colleagues, published in the same Archives of Dermatology, examined the validity of patient self-reported history of skin cancer and found meaningful discordance between what patients reported and what medical records could substantiate. That work, along with the more recent effort by Kitrell, Crew, Wysong, and Sutton in 2023 to refine the classification of field cancerization, frames the conceptual backdrop against which the new Nebraska-led study operates. The field cancerization concept itself, originally coined in the head and neck oncology literature and since extended to sun-damaged skin, implies that patients with field disease are precisely the ones most likely to have long, complicated lesion histories that strain the limits of lay recall.

Health literacy adds another layer of complexity. A 2024 systematic review by Chang and colleagues in the Journal of Prevention examined the role of health literacy in skin cancer preventive behavior and highlighted how unevenly patients understand even basic distinctions between lesion types. Many patients use the phrase skin cancer loosely, applying it to anything their doctor froze, burned, or scraped. Others with genuine histories of malignancy may not register the diagnosis because the encounter was brief, the terminology was unfamiliar, or the lesion was treated in a setting where pathology confirmation never occurred. In epidemiological surveys, in genetic studies recruiting participants on the basis of skin cancer history, and in clinical trials of field therapies, these misclassifications propagate quietly through the data.

The methodological stakes extend beyond the clinic into the research enterprise itself. Countless studies of keratinocyte carcinoma risk factors, from tanning bed use to immunosuppression to genetic susceptibility loci, rely on questionnaires asking participants whether a physician has ever told them they had skin cancer. Validation studies like the one from the University of Nebraska team provide the sensitivity and specificity estimates that allow researchers to correct for misclassification statistically. Without such grounding, effect estimates can be biased toward or away from the null in unpredictable ways, and the direction of bias often differs for actinic keratoses, which are over-reported when patients conflate them with benign barnacles of aging, versus keratinocyte carcinomas, which may be under-reported when pathology confirmation was never communicated clearly.

The practical implications for clinical practice are equally significant. Dermatologists performing surveillance on patients with a history of field cancerization already know that these individuals require more frequent examinations, and the new findings underscore that the history a patient volunteers should be treated as a starting point rather than a settled fact. Wherever possible, clinicians and researchers seeking accurate keratinocyte carcinoma histories should corroborate patient report with pathology records, tumor registries, or prior biopsy reports. For actinic keratoses, where confirmation is often impossible because destructive treatment leaves no tissue to examine, the study’s findings argue for building explicit uncertainty into both clinical documentation and research instruments, perhaps by distinguishing between patient-recalled lesions and provider-diagnosed, pathology-confirmed ones.

What makes this research letter notable is not that it overturns any single dogma but that it quantifies a vulnerability running through a vast body of dermatological science and everyday clinical care. The authors, who declare no competing interests and report no external funding, designed the study so that statistical analysis was performed by dedicated biostatisticians within the University of Nebraska Medical Center’s Department of Biostatistics, with McGrath and Fagan contributing equally to the work. Their data cannot be shared openly, a restriction that protects participant privacy under the informed consent agreements patients signed. As skin cancer incidence continues to rise and as health systems increasingly depend on patient-reported outcomes and self-administered intake tools, including digital questionnaires and telehealth screening algorithms, the gap between what patients believe about their own skin and what has actually occurred on it becomes a variable that medicine can no longer afford to ignore. This study is a measured, careful reminder that in dermatology, as in much of medicine, the patient’s memory is a diagnostic instrument, and like any instrument, it needs calibration.

Subject of Research: Accuracy of patient-reported histories of actinic keratoses and keratinocyte carcinomas

Article Title: Assessing the accuracy of patient-reported actinic keratoses and keratinocyte carcinomas

Article References: McGrath, J., Fagan, E., Samson, K., Zhan, Y., & Sutton, A. (2026). Assessing the accuracy of patient-reported actinic keratoses and keratinocyte carcinomas. Archives of Dermatological Research, 318(1), Article 489. https://doi.org/10.1007/s00403-026-04942-8

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04942-8

Keywords: actinic keratosis, keratinocyte carcinoma, skin cancer, patient self-report, dermatology, field cancerization, basal cell carcinoma, squamous cell carcinoma, health literacy, misclassification, skin cancer screening, epidemiology